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1. Introduction 
Ovarian hyperstimulation syndrome (OHSS) is a clinical symptom complex associated with 
ovarian enlargement resulting from exogenous gonadotropin therapy. In severe cases, a 
critical condition develops with massive ascites, marked ovarian enlargement, pleural 
effusion, electrolyte imbalance, hypovolemia with hypotension, oliguria, hemoconcentration, 
and thromboembolism (Madill JJ et al., 2008). Moderate to severe ovarian hyperstimulation 
syndrome (OHSS) has been calculated to occur in 0.2% to 2% of all ovarian stimulation 
cycles (Binder H et al., 2007). 
Severe OHSS can be a life-threatening complication. The prognosis is usually worse in 
patients who get pregnant and have this syndrome. 
2. Pathophysiology 
The cause of OHSS is unknown, but it may be mediated by vasoactive cytokines secreted in 
excess by hyperstimulated ovaries (Goldsman MP et al., 1995). Human chorionic 
gonadotropin (hCG), either exogenous or endogenous (derived from a resulting pregnancy), 
is believed to be an early contributing factor. Increased vascular permeability is believed to 
result from vasoactive substances produced by the corpus luteum in response to hCG 
stimulation (Chen SU et al., 2010). 
The pathophysiology of OHSS is characterized by increased vascular permeability with loss 
of fluid, protein, and electrolytes into the peritoneal cavity (Tollan A et al., 1990).  
Gastrointestinal system findings include ascites (third-spacing of fluid), paralytic ileus, and 
enlarged ovaries. Pulmonary system findings include pleural effusions, restrictive lung 
disease from ascites or paralytic ileus, and ARDS. Cardiovascular system findings include 
decreased intravascular volume, decreased blood pressure, decreased central venous 
perfusion, and compensatory increased heart rate and cardiac output with arterial 
vasodilation. Coagulation abnormalities include hemoconcentration, increased estrogen 
level leading to hypercoagulability, and thrombosis. Renal system findings include 
decreased renal perfusion with subsequent oliguria or renal failure. Hepatic system findings 
may include hepatic edema. 
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Hematologic findings include increased hematocrit (secondary to increased capillary 
permeability and fluid loss) and elevated white blood cell count, a multifactorial finding 
associated with elevated estrogen level, prostaglandins, and dilution. 
Gynecologic findings include enlarged ovaries which may torse or rupture. Finally, 
electrolyte findings classically include hyponatremia (secondary to increased antidiuretic 
hormone due to decreased intravascular volume) and hyperkalemia (secondary to the renal 
sodium/potassium pump alterations). 
3. Hemodynamic changes 
The clinical manifestations originate from the combination of decreased intravascular space 
and the accumulation of protein-rich fluid into body cavities and interstitial space. Loss of 
intravascular volume leads to hemodynamic changes manifested as hypotension, severe 
tachycardia, and decreased renal perfusion as well as hemoconcentration. 
Because hypotension leads to decreased venous pressure and reduced venous return, a 
decreased cardiac output (CO) might be expected; however, it was found the CO was 
increased in OHSS. These findings led to the determination that there is accompanying 
arterial vasodilation in OHSS (Manau D et al., 1998). 
Decreased renal perfusion leads to a decreased glomerular filtration rate (GFR), and can result 
in oliguria. Changes in perfusion can affect liver function, including synthesis of proteins, of 
which anticlotting factors are among the first to become depleted (Fabreuges F et al., 1999). 
Hemoconcentration with increase in blood coagulability is responsible for arterial and 
venous thrombotic phenomena in patients with OHSS (Chan WS et al., 2009).  
Loss of intravascular volume combined with decreased renal perfusion results in electrolyte 
abnormalities (hyperkalemia, hyponatremia), increase in hematocrit and white cell count, 
and decrease in creatinine clearance. 
Abdominal discomfort is the most common symptom of OHSS because of the 
development of ascites. Accumulation of protein-rich fluid in the peritoneal cavity leads 
to abdominal distention and increased intra-abdominal pressure (IAP). Increased IAP 
may compromise respiratory, cardiovascular, renal, gastrointestinal and hepatic system 
homeostasis (Selgas R et al., 2010).  
More reccently, vascular endothelial growth factor (VEGF), has emerged as one of the 
factors most likely to be involved in the patophysiology of OHSS. VEGF is a vasoactive 
glycoprotein (cytokine) which stimulates endothelial cell proliferation, cell permeability, 
and angiogenesis.  
Recent studies indicate that hCG is the main factor that triggers OHSS and seems to be the 
main stimulus of the syndrome because elimination of hCG will prevent the full-blown 
picture of the syndrome (Soares SR et al., 2008). It has been clearly demonstrated that hCG 
increases VEGF and its VEGF-2 receptors (VEGFR-2) in human granulosa-lutein cells and 
raises serum VEGF concentration.  
VEGF causes an increase in vascular permeability by rearranging endothelial junction 
proteins, including cadherin and claudin 5. When evaluating human endothelial cells from 
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umbilical veins (used as an in vitro model of OHSS), hCG and VEGF caused changes in the 
actin fibers that are indicative of increased capillary permeability, and cadherin 
concentration was elevated when hCG and VEGF were added, but not with the addition of 
estradiol (Villasante A et al., 2007). Cadherin is a soluble cell adhesion molecule that may 
play a key role in the pathophysiology and progression of vascular hyperpermeability 
(Villasante A et al., 2007). 
4. Classification of OHSS 
Conventional OHSS staging has relied on clinical symptoms and laboratory findings to 
categorize severity of disease. The most popular classification system for staging OHSS is 
that of Golan et al., 1989. This system incorporated the use of transvaginal sonography for 
both estimating of ovarian enlargement and detection of ascites. The detection of ascites 
establishes the diagnosis of moderate OHSS which may deteriorate to a severe form and is 
therefore of major importance. Subsequent modifications defined a group of critical OHSS 




Mild abdominal pain 
Ovarian size usually <8cm* 
Moderate OHSS 
Moderate abdominal pain 
Nausea +/- vomiting 
Ultrasound evidence of ascites 
Ovarian size usually 8-12 cm* 
Severe OHSS 
Clinical ascites (occasionally hydrothorax) 
Oliguria 
Haemoconcentracion hematocrit >45% 
Hypoproteinaemia 
Ovarian size usually >12 cm* 
Critical OHSS 
Tense ascites or large hydrothorax 
Haematocrit >55% 
Whitw cell count >25 000/ml 
Oligo/anuria 
Tromboembolism 
Acute respiratory distress syndrome (ARDS) 
*Ovarian size may not correlate with severity of OHSS in cases of assisted reproduction because of the 
effect of follicular aspiration 
Table 1. Classification of severity of OHSS 
Depending on the time of onset, a division of OHSS into ‘early’ and ‘late’ may be useful in 
determining the prognosis. OHSS presenting within 9 days after the ovulatory dose of hCG 
is likely to reflect excessive ovarian response and the precipitating effect of exogenous hCG 
administered for final follicular maturation. OHSS presenting after this period reflects 
endogenous hCG stimulation from an early pregnancy. Late OHSS is more likely to be 
severe and to last longer than early OHSS (Mathur RS et al., 2000). 
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5. Risk factors 
The following factors increase the risk independently for the development of OHSS (Enskog 
A. et al., 1999): 
 young age 
 low body mass index (BMI) 
 polycystic ovarian syndrome (PCOS) 
 allergic history 
 high antral follicle count 
 high doses of gonadotropins 
 high or rapidly rising estradiol levels 
 large numbers of large and medium-sized follicles 
 large numbers of oocytes retrieved 
 high or repeated doses of hCG 
 pregnancy 
 prior OHSS 
High or rapidly rising estradiol levels are particularly unreliable and over-rated predictors 
of OHSS (Papanikolau EG et al., 2006). 
An estradiol cut-off of 3,000 pg/mL will miss 2/3 of patients with severe OHSS. Counting 
the number of 12mm follicles is actually a better predictor of OHSS than serum estradiol 
levels, and the combination of an estradiol level of 5,000 pg/mL and eighteen 12mm follicles 
was found to be the best predictor of OHSS in this study, yielding a sensitivity of 83% and 
specificity of 84 %(Papanikolau EG et al., 2006). 
6. Prevention 
The keys to preventing OHSS are experience with ovulation induction therapy and 
recognition of risk factors for OHSS. 
Caution is indicated when any of the following indicators for increased risk of OHSS are 
present (Practice Committee of American Society for Reproductive Medicine, 2008) :  
 rapidly rising serum E2 levels 
 E2 concentration in excess of 2500 pg/ml 
 the emergence of a large number of intermediate sized follicles (10-14mm) 
 OHSS prevention has historically included the following strategies: 
6.1 Cycle cancellation  
IVF cycle cancellation with withholding of hCG trigger is the most effective preventative 
technique, but is emotionally and financially stressful for all involved. Cycle cancellation is 
generally reserved for patients with a history of severe OHSS in a prior cycle and in cases of 
total loss of control of the cycle. 
6.2 Coasting 
Coasting involves temporarily stopping gonadotropin administration and postponing the 
hCG trigger until the estradiol (E2) level is lower. The proposed mechanism of coasting is as 
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follows: lower gonadotropin stimulation leads to decreased LH receptors, leading to 
decreased luteinization, and subsequent decreased VEGF levels. Lower gonadotropin 
stimulation may also increase the rate of granulose cell apoptosis, especially of smaller 
follicles. Coasting lowers the level of follicular fluid VEGF, thereby potentially preventing 
the development of OHSS (Tozer AJ et al., 2004). 
It is a good alternative that can be used to avoid cycle cancellation in extremely high 
responders to ovulation induction, who have high risk of developing severe OHSS. Even 
if OHSS develops after coasting, both incidence and severity will be diminished. 
However, prolonged coasting has a drawback of a reduced pregnancy rate (Garcia-
Velasco JA et al., 2006). 
6.3 Decreasing the dose of hCG trigger 
Although theoretically it makes sense to reduce the dose of hCG, there is little data to 
support this practice and studies are either limited by small sample size or not powered to 
detect a difference. 
6.4 Agonist trigger 
Using an agonist medication to trigger ovulation has been proposed as another strategy to 
prevent OHSS. Agonist trigger can only be used in the setting of an antagonist protocol.  
Comparing pregnancy rate per patient randomized to GnRH agonist vs. hCG trigger 
identified no difference in number of oocytes retrieved, fertilization rate, or embryo score. 
No patients randomized to either GnRH agonist or hCG trigger developed OHSS; but there 
was the suggestion of a lower pregnancy rate in patients who had GnRH agonist trigger, 
possibly due to a luteal support problem (Griesinger G et al, 2006). 
6.5 Cryopreservation of all embrios 
Certainly the concept of cryopreservation of all embryos seems logical as a strategy to 
prevent OHSS given that OHSS is more common and more severe with pregnancy due to 
hCG-induced intrinsic ovarian stimulation. 
Sills et al. in 2008 analyzed outcomes in patients undergoing elective embryo cryopreservation 
to prophylax against the development of OHSS (Sills ES et al., 2008). 
Elective transfer of a single zona-free day 5 embryo and freezing of the supernumerary 
embryos or cryopreservation of all embryos for postponement of transfer can prevent the 
occurrence of late OHSS from pregnancy. However, it does not prevent early OHSS 
development due to exogenous hCG administration. The management based on elective 
2 pronucleate embryo cryopreservation with subsequent thaw and grow-out to 
blastocyst stage for trasnsfer did not appear to compromise embryo viability or overall 
reproductive outcome.  
The mean number of days from embryo cryopreservation to date of thaw embryo transfer 
was 115 (range 30–377), and embryo blastulation rate was 88%. Finally, the live birth rate 
per embryo transfer was an excellent 43.6% in these patients. 
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However, the Cochrane review found insufficient evidence in the literature to support the 
routine practice of embryo cryopreservation to prevent OHSS (D’ Angelo A et al., 2002). As 
with all methods, it may reduce but not eliminate OHSS.  
6.6 Intravenous albumin at the time of oocyte retrieval 
Albumin is a low molecular weight plasma compound with a major impact on oncotic 
pressure. Human albumin has been used on the day of hCG administration in high-risk 
women to prevent OHSS. However, in a recent prospective randomized study, it was found 
that human albumin did not seem either to prevent or to reduce the incidence of severe 
OHSS. Without a concomitant reduction in vascular permeability, however, the effect of 
albumin on intravascular volume and hematocrit may be of short duration due to its 
diffusion into extravascular space, exacerbating both ascites and pleural effusions (Isikoglu 
M et al., 2007). 
6.7 Non-steroidal anti-inflammatory administration 
Low-dose aspirin therapy (100 mg daily, beginning on the first day of ovarian 
stimulation) was shown to be effective in preventing OHSS among high risk women in a 
recent study (Varnagy A et al., 2010). This study evaluated 2,425 cycles in which 
gonadotropin-releasing hormone agonist was used. Among 1,192 women at a high risk for 
developing OHSS, 780 randomly received aspirin, and the incidence of OHSS was 0.25% 
compared with 8.4% among the 412 women who did not receive aspirin. The pregnancy 
rates were similar. 
6.8 Dopamine agonist 
The most recently suggested strategy to prevent the development of OHSS is the use of 
dopamine agonists such as Cabergoline. The proposed mechanism is inhibition of 
phosphorylation of the VEGF receptor by Cabergoline, thereby preventing increased 
capillary permeability, the main action of VEGF.  
In study by Alvarez et al. (2007), patients were assigned to receive either Cabergoline 
0.5mg/day for 8 days starting on the day of hCG (35 patients) or placebo (32 patients). All 
patients underwent evaluation for OHSS, including serum hematocrit, ultrasound to 
evaluate for ascites, and magnetic resonance imaging (MRI) for ovarian venous 
permeability. They found that in the women who received Cabergoline, the ascites volume 
was statistically significantly lower than in those who received placebo. They also found 
that the percentage of women who developed moderate OHSS was statistically significantly 
lower in those patients who received Cabergoline. There was no difference in the percentage 
of patients in each group who developed severe OHSS.  
In spite of these beneficial effects of the dopamine agonist cabergoline on vascular 
permeability without compromising implantation and pregnancy rates, this treatment 
would complement the ongoing progress with ither procedures such as in vitro maturation 
and oocyte vitrification and enable physicians to predict and prevent OHSS (Garcia-Velasco 
Ja et al., 2009).  
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6.9 In vitro maturation of oocytes (IVM) 
The safest way to prevent OHSS would be by not stimulating the ovaries. During an IVM 
cycle, immature oocytes are retrieved from barely stimulated or completely unstimulated 
ovaries. The oocytes are matured in defined culture media for 24–48 h and then fertilized by 
in vitro fertilization or intracytoplasmatic sperm injection. The embryo transfer is performed 
as usual; normally two embryos are transferred in two or three days after fertilization. The 
lack of ovarian stimulation during IVM cycles brings many benefits, including the 
following: reduction in medication cost, no risk for OHSS, and a reduction in the total 
number of patient visits for clinical and laboratory evaluations (Lazendorf SE et al., 2006). 
Clinical trials evaluating IVM performed in women with PCOS demonstrated good 
pregnancy ratio per embryo transferred (20–54%) and good implantation rates (5.5–34.5%) 
(Suikkari aM et al., 2008). When evaluating IVM performed in ovulatory women, the results 
were a little worse, with pregnancy per embryo transfer rates between 15 and 33.3% and 
implantation rates between 8.8 and 22.6%.  
Although good results have been reported by some clinics, IVM has not yet become a 
mainstream fertility treatment. The most important reasons are: technical difficulties for 
retrieving immature oocytes from unstimulated ovaries and to cultivate them, lower chance 
of a live birth per treatment compared with conventional in vitro fertilization, the report of 
higher rates of meiotic spindle and chromosome abnormalities from immature human 
oocytes (Lazendorf SE et al., 2006). 
7. Management 
7.1 Outpatient management 
Patients with mild manifestation of OHSS do not require any specific treatment. Outpatient 
surveillance is, nevertheless, mandatory to detect cases that may progress to moderate or 
severe OHSS. Most patients with moderate OHSS still can be managed on an outpatient 
basis, but they require more careful evaluation including daily weight and abdominal girth 
measurement, physical and ultrasound examination to detect increasing ascites, and to 
measure ovarian size. Oral fluid intake should be maintained at no less than 1 L per day. 
Women should be encouraged to drink to thirst, rather than to excess. Strenuous exercise 
and sexual intercourse should be avoided. Strict bed rest is unwarranted and may increase 
risk of thromboembolism. Progesterone supplementation is continued in the luteal phase, 
but supplementation is never done with hCG. 
Discomfort may be relieved with acetaminophen or opiate medications if severe. 
Nonsteroidal anti-inflammatory agents are not recommended because they may 
compromise renal function in patients with OHSS. 
Laboratory investigations that are helpful in assessing the severity of OHSS are 
haemoglobin,haematocrit, serum creatinine and electrolytes and liver function tests. 
Baseline values may help track the progress of the condition. 
Review every 2–3 days is likely to be adequate. However, urgent clinical review is necessary if 
the woman develops increasing severity of pain, increasing abdominal distension, shortness of 
breath and a subjective impression of reduced urine output (Jenkins JM et al., 2006). 
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7.2 Hospital management 
Women with serious illness or severe OHSS require hospitalization for more careful 
monitoring and aggressive treatment. Careful and frequent reevaluation of the hospitalized 
patient with severe OHSS is essential. Clinical examination includes an assessment of 
hydration and cardiorespiratory system. Abdominal circumference and weight should be 
recorded at admission and daily until resolution. Fluid intake and output should be 
recorded and monitored on at least a daily basis. Urine output of less than 1,000 mL/day is 
a matter of concern. 
Biochemical monitoring should include serum electrolytes, renal and liver function tests, a 
coagulation profile, and blood count. Sonographic examination provides assessment of 
ovarian size and the presence of ascites as well as pleural, or pericardial effusions. A chest 
X-ray and pulse oximetry are mandatory for any patient with respiratory symptoms and 
signs suggestive of hydrothorax, pulmonary infection, or pulmonary embolism. Assay of b-
hCG will help to diagnose pregnancy as early as possible. Pain and ascites can easily mask 
adnexal torsion, ovarian rupture, and acute intra-abdominal hemorrhage. Serial clinical and 
laboratory evaluations provide the means to monitor progression of illness and to recognize 
evidence of resolution (Jenkins et al., 2006). 
Antiemetic drugs used should be those appropriate for the possibility of early pregnancy, 
such as prochlorperazine, metoclopramide and cyclizine. 
The management of OHSS is essentially supportive until the condition resolves 
spontaneously. 
Symptomatic relief is important, particularly regarding pain and nausea. Discomfort may be 
relieved with paracetamol or opiate medications if severe. If opiates are used, particularly in 
women with reduced mobility, care should be taken to avoid constipation. Nausea is 
usually related to the accumulation of ascites and so measures described to reduce 
abdominal distension should provide relief. Counselling support for both the woman and 
her partner provides reassurance and information to allay anxiety. 
Regarding fluid management, it is critical to correct hemoconcentration. It is recommended 
to start with an initial IV fluid bolus of 500–1,000cc normal saline (NS) over the first hour of 
admission, followed by rehydration at a decreased rate of 30cc/hour using D5NS titrated to 
urine output. Oral fluid intake should be reduced to thirst and patient comfort. Albumin 
(25%) may be needed for intravascular volume repletion, in which case 50 –100gm of IV 
albumin is infused over 4 hours and repeated at 4–12 hour intervals as needed. 
Hyperkalemia is treated in the standard manner with Kayexelate, insulin/glucose, sodium 
bicarbonate, or albuterol as needed. Rarely, diuretics can be given, but extreme caution is 
used in the administration of diuretics to patients with OHSS given their known 
intravascular volume depletion. Other inpatient management strategies include paracentesis 
if needed. Thromboembolism prevention is critical given the hypercoagulatory state of 
OHSS. It is generally recommended both venous support stockings and anticoagulants such 
as heparin 5,000 U subcutaneously twice daily. Occasionally, patients may need intensive 
care unit admission for thromboembolic complications, renal failure, or if invasive 
hemodynamic monitoring is indicated (central venous pressure, pulmonary capillary wedge 
pressure) (Alper MM et al., 2009). 
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